Your institution may have access to this item. Find your institution then sign in to continue.
Title
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.
Authors
A. H. G. Hansma; H. J. Broxterman; I. van der Horst; Y. Yuana; E. Boven; G. Giaccone; H. M. Pinedo; K. Hoekman